U.S. markets closed

Chembio Diagnostics, Inc. (CEMI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7030+0.0079 (+1.14%)
At close: 04:00PM EDT
0.7377 +0.03 (+4.94%)
After hours: 06:16PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.6951
Bid0.7030 x 4000
Ask0.7400 x 2200
Day's Range0.6950 - 0.7800
52 Week Range0.4200 - 7.3400
Avg. Volume265,114
Market Cap21.246M
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-1.4260
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CEMI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Chembio Diagnostics, Inc.
    OSUR: Rating increased to a HOLDORASURE TECHNOLOGIES INC has an Investment Rating of HOLD; a target price of $4.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors

    HAUPPAUGE, N.Y., May 24, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the election of Leslie Teso-Lichtman to its Board of Directors at Chembio’s 2022 Annual Meeting of Stockholders. “We are excited to have Leslie join the Chembio Board of Directors,” said Richard Eberly, Chembio’s Chief Executive Officer and President. “Her significant experience in corporate financial lead

  • GlobeNewswire

    Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility

    HAUPPAUGE, N.Y., May 17, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has entered into a manufacturing agreement with Reszon Diagnostics International Sdn. Bhd. (Reszon) to produce Chembio’s HIV 1/2 STAT-PAK Assay products in the Chembio Diagnostics Malaysia (CDM) facility. CDM had previously suspended operations in May 2020. This new manufacturing arrangement will levera

  • GlobeNewswire

    Chembio Diagnostics Reports First Quarter 2022 Financial Results

    HAUPPAUGE, N.Y., May 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2022. Recent Highlights Achieved total revenue of $18.8 million including record quarterly product revenue of $18.5 million in the first quarter of 2022, representing growth of 116% and 360%, respectively, compared to the prior year perio